Zions Bancorporation N.A. Sells 713 Shares of Boston Scientific Co. (NYSE:BSX)

Zions Bancorporation N.A. lessened its position in shares of Boston Scientific Co. (NYSE:BSX) by 17.9% in the third quarter, HoldingsChannel.com reports. The fund owned 3,280 shares of the medical equipment provider’s stock after selling 713 shares during the period. Zions Bancorporation N.A.’s holdings in Boston Scientific were worth $275,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BSX. KBC Group NV boosted its holdings in shares of Boston Scientific by 24.3% in the 3rd quarter. KBC Group NV now owns 2,338,801 shares of the medical equipment provider’s stock valued at $195,991,000 after purchasing an additional 457,383 shares in the last quarter. Huntington National Bank boosted its stake in Boston Scientific by 7.6% in the third quarter. Huntington National Bank now owns 1,198,556 shares of the medical equipment provider’s stock valued at $100,439,000 after buying an additional 84,830 shares in the last quarter. Bouvel Investment Partners LLC raised its stake in Boston Scientific by 1.6% during the third quarter. Bouvel Investment Partners LLC now owns 45,148 shares of the medical equipment provider’s stock worth $3,783,000 after acquiring an additional 702 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Boston Scientific during the third quarter worth about $84,000. Finally, Saturna Capital Corp lifted its stake in Boston Scientific by 1.5% in the 3rd quarter. Saturna Capital Corp now owns 26,500 shares of the medical equipment provider’s stock valued at $2,221,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on BSX shares. Canaccord Genuity Group increased their price target on Boston Scientific from $88.00 to $98.00 and gave the company a “buy” rating in a research note on Monday, October 21st. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Truist Financial upped their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $93.39.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares in the company, valued at $2,913,967.28. This trade represents a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 45.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 309,270 shares of company stock valued at $26,196,718. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.7 %

Boston Scientific stock opened at $86.98 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $128.19 billion, a PE ratio of 71.88, a PEG ratio of 2.61 and a beta of 0.79. The firm’s fifty day moving average is $85.15 and its 200 day moving average is $79.39. Boston Scientific Co. has a 12-month low of $53.56 and a 12-month high of $89.30.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the prior year, the firm earned $0.50 EPS. The business’s revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.